Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Biodexa gain rights to develop and commercialize MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase and Phase II Ready Asset for Type 1 Diabetes.
Brand Name : MLR-1023
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 27, 2023
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : MLR-1019 (armesocarb) is is the active enantiomer in mesocarb, a new class of drug for Parkinson’s Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD.
Brand Name : MLR-1019
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2021
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Melior Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Adhera Inks Exclusive License Agreement with Melior Pharmaceuticals for MLR-1023
Details : Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b ...
Brand Name : MLR-102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Melior Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?